Given the clinical development of BPX-01 for the treatment of acne and the similarities between acne and rosacea, BioPharmX is also pursuing development of its lead product candidate in the indication for rosacea. We are currently evaluating BPX-01 in an open-label study consisting of up to 20 subjects with moderate-to-severe papulopustular rosacea. The study uses a 12-week once-daily treatment using BPX-01 1% minocycline.

Based on results from a four-week tolerability assessment, the company will evaluate moving forward into a phase 2/3 pivotal study in this indication. The phase 2/3 study will evaluate the safety and efficacy of BPX-01 for the treatment of moderate-to-severe papulopustular rosacea.